Quest Diagnostics
654 hedge funds and large institutions have $13.2B invested in Quest Diagnostics in 2019 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 229 increasing their positions, 232 reducing their positions, and 65 closing their positions.
41% more call options, than puts
Call options by funds: $36.3M | Put options by funds: $25.8M
18% more capital invested
Capital invested by funds: $11.2B → $13.2B (+$2.04B)
9% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 65
0% less funds holding
Funds holding: 656 → 654 (-2)
1% less repeat investments, than reductions
Existing positions increased: 229 | Existing positions reduced: 232
1.77% less ownership
Funds ownership: 92.87% → 91.1% (-1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$84.2M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$70.1M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$54.9M |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$46.8M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$43.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$113M |
| 2 |
EIP
Easterly Investment Partners
Beverly,
Massachusetts
|
-$104M |
| 3 |
Two Sigma Advisers
New York
|
-$58.3M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$56.6M |
| 5 |
Two Sigma Investments
New York
|
-$56.1M |
DGX Hedge Fund Activity: Q2 2019 in Review
654 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q2 2019, worth a combined $13.2B — up 18% from $11.2B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new DGX positions and 65 closed out — a net gain of 6 holders — while 229 added to existing stakes and 232 trimmed.
The largest buyer was Fidelity International, adding an estimated $84.2M. The largest seller was BlackRock, cutting an estimated $113M.
- 654 institutional investors held Quest Diagnostics (DGX) as of Q2 2019, down from 656 in Q1 2019.
- Funds reported $13.2B of Quest Diagnostics stock for Q2 2019, up 18% quarter-over-quarter.
- 71 funds opened new Quest Diagnostics positions in Q2 2019 and 65 closed out, a net change of +6 holders.
- The largest Quest Diagnostics buyer in Q2 2019 was Fidelity International, an estimated $84.2M added.
- The largest Quest Diagnostics seller in Q2 2019 was BlackRock, an estimated $113M sold.
Based on aggregated 13F filings for Q2 2019.